Index · Artikel · AIDS gel with Gilead drug protects women in study

AIDS gel with Gilead drug protects women in study

2010-07-19 4
   
Advertisement
résuméVIENNA A gel containing a prescription drug can sharply reduce HIV infections in women, a study described as groundbreaking by the World Health Organization showed on Monday. The gel, containing Gilead Sciences AIDS drug tenofovir, reduced HIV infect
Advertisement

AIDS gel with Gilead drug protects women in study


VIENNA A gel containing a prescription drug can sharply reduce HIV infections in women, a study described as groundbreaking by the World Health Organization showed on Monday.

The gel, containing Gilead Sciences AIDS drug tenofovir, reduced HIV infections in women by 39 percent over two and a half years -- the first time such an approach has protected against sexual transmission of the virus.

The findings, presented at an international AIDS conference in Vienna, were described as "groundbreaking" by the World Health Organization and the United Nation's AIDS group (UNAIDS).

They show it may be possible to slow the spread of the disease by giving women a way to protect themselves.

"Boy, have we been doing the happy dance," Dr. Salim Abdool Karim, from the University of KwaZulu-Natal in Durban, said of the South African findings.

The gel also cut the risk a woman would get genital herpes by 51 percent, a surprise result that adds further benefits.

The trial of 889 women in the coastal city of Durban and a remote rural village showed women largely used the gel as directed, Karim said, answering an important question about whether such a product could work in the real world.

Shares of Gilead were up 3 percent at $32.90 in afternoon trading on the Nasdaq exchange.

The study was funded by the South African government and USAID. Gilead supplied the drug for no charge but was not otherwise involved.

Margaret Chan, director general of the WHO, described the findings as "exciting."

"We look forward to seeing these results confirmed. Once they have been shown to be safe and effective, the WHO will work with countries and partners to accelerate access to these products," she said in a statement to the Vienna conference.

UNAIDS director Michel Sidibe, also at the conference, said it could become "a powerful option for the prevention revolution and help us break the trajectory of the AIDS epidemic."

Researchers have been trying for years to formulate a microbicide -- a gel, cream, ring or tablet inserted into the vagina or rectum before sex to prevent transmission of the human immunodeficiency virus that causes AIDS.

But past efforts have had disappointing results.

CAPRISA TRIAL

In this test of a microbicide, called Caprisa, researchers used for the first time a prescription HIV drug in the mix, Gilead's tenofovir. Studies in monkeys have strongly suggested it can protect against both vaginal and rectal infection.

In Africa, where most of the world's 33 million HIV cases are, most new cases are in young women infected by older men. Young boys aged 15-19 do not have high rates of HIV, but girls this age already do.

The Caprisa trial was a classic medical clinical study, with half the women using the gel before and after sex, and half being given a placebo. No one knew who got the real drug.

The women kept track of the applicators, which resemble applicators used to insert tampons, and gave them to researchers so they could be sure when the gel was actually used.

All the women were also given condoms and advice about sexually transmitted diseases, and tested for HIV once a month.

After 30 months, 98 women became infected with HIV -- 38 in the group that got tenofovir in the gel and 60 in the group that got placebos. "We showed a 39 percent lower incidence of HIV in the tenofovir group," Karim said.

When they checked the data, it turned out that tenofovir lowered the risk of infection by 50 percent at 12 months but then the efficacy declined. Women who used the gel more consistently were much less likely to be infected.

"Why is our effectiveness going down over time? Essentially it is a matter of adherence," Karim said. "We are telling these women we have no idea if this works and we are also telling them we don't know it is safe."

If women understand the gel will protect them Karim said, he believes they will use it more consistently. He added he did not know how much each dose would cost but said the applicators and gel cost just pennies.

(Reporting by Maggie Fox in Washington, Deena Beasley in Los Angeles and Kate Kelland in Vienna)

(Editing by Frances Kerry and Maria Golovnina)

  • AIDS gel with Gilead drug protects women in study

    AIDS gel with Gilead drug protects women in study
    VIENNA A gel containing a prescription drug can sharply reduce HIV infections in women, a study described as groundbreaking by the World Health Organization showed on Monday. The gel, containing Gilead Sciences AIDS drug tenofovir, reduced HIV infect
    2010-07-19 AIDSGEL
  • Future of AIDS gels may lie in drugs, experts say

    Future of AIDS gels may lie in drugs, experts say
    WASHINGTON The quest for a cream or gel to prevent AIDS infection has narrowed to using powerful HIV pills that are already on the market, scientists say. AIDS experts have long been searching for a microbicide -- a cream, gel or vaginal ring that wo
    2010-02-21 AIDSPREVENTION
  • S.Africa eager to see speedy roll-out of AIDS gel

    S.Africa eager to see speedy roll-out of AIDS gel
    VIENNA South Africa is considering rolling out use of a vaginal gel which can protect women against HIV during sex before it is officially licensed by drug regulators, the country's health minister said on Tuesday. Speaking at an international AIDS c
    2010-07-20 AIDSGELSAFRICA
  • Groups moving forward to develop AIDS gel

    Groups moving forward to develop AIDS gel
    WASHINGTON Groups developing a gel to protect women from the AIDS virus say they are moving ahead to develop the product that was hailed as "groundbreaking" after a study on its effectiveness was released in July. The developers, who met last we
    2010-10-27 AIDSGEL
  • AIDS drug cocktails saving lives: study

    AIDS drug cocktails saving lives: study
    NEW YORK (Reuters Health) - Taking a cocktail of powerful AIDS drugs appears to have cut the average death rate by half in a group of people infected with HIV, the virus that causes AIDS, who were followed for an average of more than three years. In
    2010-01-04 AIDSCOCKTAILS
  • Drugs protect monkeys from Ebola, U.S. study finds

    Drugs protect monkeys from Ebola, U.S. study finds
    WASHINGTON U.S. government researchers working to find ways to treat the highly deadly Ebola virus said on Sunday a new approach from AVI BioPharma Inc saved monkeys after they were infected. Two experimental treatments protected more than 60 percent
    2010-08-23 DRUGEBOLA
  • Nausea drug safe for fetus: study

    Nausea drug safe for fetus: study
    BOSTON An anti-nausea drug that is widely used but little tested for safety in pregnant women does no obvious harm to the fetus, an Israeli study of thousands of users concluded on Wednesday. Investigators found no increase in death or malformations
    2009-06-11 PREGNANCYNAUSEA
  • New Bristol, Pfizer clot drug saves lives in study

    New Bristol, Pfizer clot drug saves lives in study
    PARIS An experimental anti-clotting drug from Bristol-Myers Squibb and Pfizer saved more lives than standard treatment warfarin in a major study, giving it an edge over rivals in an emerging multibillion-dollar market. Although Eliquis will be third
    2011-08-28 HEARTPFIZERBRISTOL
  • New Daiichi drug succeeds in major study; set to face rivals

    New Daiichi drug succeeds in major study; set to face rivals
    DALLAS A new blood clot and stroke preventer from Daiichi Sankyo proved as effective and safer than widely used warfarin in a large, late stage trial of patients with atrial fibrillation, paving the way for it to compete with other new warfarin alter
  • Typhoid vaccine protects younger children: study

    Typhoid vaccine protects younger children: study
    BOSTON GlaxoSmithKline's Typherix vaccine shields children as young as 2 from typhoid fever, and widespread vaccination can even protect people who have not been given the shot, according to a study published on Wednesday. The test, conducted in two
    2009-07-22 VACCINETYPHOID
  • Pfizer heart-failure drug helps milder patients: study

    Pfizer heart-failure drug helps milder patients: study
    CHICAGO People with mild heart failure lived longer and fared better by adding Pfizer's drug Inspra to standard medications, a finding that could widely expand use of such drugs in healthier patients, researchers said on Sunday. In an ironic twist, a
    2010-11-14 HEARTDRUGSFAILURE
  • Early anti-smoking drug start seems better: study

    Early anti-smoking drug start seems better: study
    NEW YORK (Reuters Health) - Getting a head start on Pfizer's anti-smoking drug Chantix may help smokers kick the habit, according to a preliminary study funded by the company. More than a third of smokers who started on the drug a month before quitti
    2011-04-25 STUDYANTISMOKING
  • Pfizer's quit smoking drug raises heart risks: study

    Pfizer's quit smoking drug raises heart risks: study
    LONDON Healthy, middle-aged smokers who take Pfizer's Chantix or Champix, one of the most popular quit-smoking drugs, have a higher risk of suffering heart attacks or other serious heart problems, a study found on Monday. British and American scienti
  • Evidence behind autism drugs may be biased: study

    Evidence behind autism drugs may be biased: study
    NEW YORK (Reuters Health) - Doctors' belief that certain antidepressants can help to treat repetitive behaviors in kids with autism may be based on incomplete information, according to a new review of published and unpublished research. The drugs, wh
  • Merck's once-a-week diabetes drug effective in clinical study

    Merck's once-a-week diabetes drug effective in clinical study
    n">An experimental once-a-week drug for type 2 diabetes being developed by Merck & Co proved effective in lowering blood sugar levels in a mid-stage clinical trial, according to data presented on Wednesday. The pill, known as MK-3102, is from
    2012-10-03 DIABETESMERCK
  • Regeneron drug tames eczema in study

    Regeneron drug tames eczema in study
    PARIS/NEW YORK An experimental drug from Sanofi and Regeneron Pharmaceuticals Inc significantly reduced skin lesions and itching in adult patients with atopic dermatitis, a chronic form of eczema that is poorly controlled by standard drugs, the compa
  • HIV/AIDS drug puzzle cracked

    HIV/AIDS drug puzzle cracked
    LONDON Scientists say they have solved a crucial puzzle about the AIDS virus after 20 years of research and that their findings could lead to better treatments for HIV. British and U.S. researchers said they had grown a crystal that enabled them to s
    2010-02-01 AIDSHIVENZYME
  • GSK's HIV drug beats Gilead market leader in study

    GSK's HIV drug beats Gilead market leader in study
    LONDON An experimental once-daily AIDS drug from GlaxoSmithKline and its Japanese partner Shionogi proved better than Gilead's market-leading Atripla in a late-stage clinical trial, increasing hopes for the product. Dolutegravir, which could reach th
  • GlaxoSmithKline unit joins patent pool for AIDS drugs

    GlaxoSmithKline unit joins patent pool for AIDS drugs
    LONDON GlaxoSmithKline's HIV/AIDS drugs business is to share intellectual property rights on children's medicine in a patent pool designed to make treatments more widely available in poor countries. ViiV Healthcare, majority-owned by GSK, is the seco
    2013-02-27 AIDSDRUGSPATENTS
  • Women are missing from HIV drug trials

    Women are missing from HIV drug trials
    n">(Reuters Health) - Although women make up roughly half of the world's HIV cases, they remain largely excluded from clinical trials testing drugs, vaccines and potential cures for the virus, a research review confirms. In an analysis spanning se
    2015-10-02 WOMENHEALTHHIV

TOP

  • Day/
  • Week/
  • Original/
  • Recommand

Updated